In adults, mutations in IDH1 or IDH2 confer a significant survival benefit in histologically lower-grade astrocytomas compared to their IDH-wildtype counterparts, and as such, is the most important prognostic factor in this group [4]. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).